Cytomegalovirus Prevention in High-risk Lung Transplant Recipients: Comparison of 3- vs 12-Month Valganciclovir Therapy
- 15 May 2009
- journal article
- clinical trial
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 28 (7) , 670-675
- https://doi.org/10.1016/j.healun.2009.03.012
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Cytomegalovirus in transplantation – challenging thestatus quoClinical Transplantation, 2007
- Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab InductionAmerican Journal of Transplantation, 2003
- Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantationTransplant Infectious Disease, 2001
- Infectious complications of lung transplantationTransplant Infectious Disease, 2001
- Costs and Outcomes of Prolonged Cytomegalovirus Prophylaxis to Cover the Enhanced Immunosuppression Phase Following Lung TransplantationChest, 1999
- EFFICACY AND COST EFFECTIVENESS OF ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER LUNG TRANSPLANTATION1,2Transplantation, 1999
- Cytomegalovirus Viremia in Lung Transplant Recipients Receiving Ganciclovir and Immune GlobulinChest, 1998
- Bronchiolitis Obliterans in Recipients of Single, Double, and Heart-Lung TransplantationChest, 1995
- A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.American Journal of Respiratory and Critical Care Medicine, 1994
- CYTOMEGALOVIRUS SEROLOGIC STATUS AND POSTOPERATIVE INFECTION CORRELATED WITH RISK OF DEVELOPING CHRONIC REJECTION AFTER PULMONARY TRANSPLANTATIONTransplantation, 1991